Market Closed -
Nasdaq
16:00:00 2024-05-31 EDT
5-day change
1st Jan Change
0.271
USD
-1.09%
+0.37%
-88.52%
Presentation Operator MessageOperator (Operator)Good morning, and thank you all for joining Gl...
GlycoMimetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-09
CI
Capital One Downgrades GlycoMimetics to Equalweight, Price Target at $0.50
05-07
MT
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
05-06
MT
Sector Update: Health Care
05-06
MT
GlycoMimetics Shares Slump After Cancer Treatment Drug Combination Fails to Meet Primary Endpoint
05-06
MT
Transcript : GlycoMimetics, Inc., Q1 2024 Earnings Call, May 06, 2024
05-06
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia
05-06
CI
Transcript : GlycoMimetics, Inc., Q4 2023 Earnings Call, Mar 27, 2024
03-27
GlycoMimetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
03-27
CI
GlycoMimetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
03-27
CI
North American Morning Briefing : Stocks Edge -2-
03-27
DJ
GlycoMimetics, Inc. Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1A Healthy Volunteer Study of GMI-1687
01-04
CI
GlycoMimetics, Thermo Fisher Unit Set Accord for Manufacturing Uproleselan for Acute Myeloid Leukemia
01-02
MT
Capital One Initiates GlycoMimetics With Overweight Rating, Price Target is $12
12-22
MT
GlycoMimetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-03
CI
Transcript : GlycoMimetics, Inc., Q3 2023 Earnings Call, Nov 03, 2023
11-03
GlycoMimetics, Inc. Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
23-09-06
CI
Transcript : GlycoMimetics, Inc., Q2 2023 Earnings Call, Aug 02, 2023
23-08-02
GlycoMimetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-02
CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell 3000E Growth Index
23-06-23
CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell Microcap Value Index
23-06-23
CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell 3000E Value Index
23-06-23
CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell Microcap Growth Index
23-06-23
CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell 3000E Index
23-06-23
CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell Microcap Index
23-06-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).
More about the company
Last Close Price
0.271
USD
Average target price
0.75
USD
Spread / Average Target
+176.75%
Consensus
1st Jan change
Capi.
-88.52% 17.47M +11.60% 106B -4.68% 24.28B -0.82% 21.96B -10.12% 18.16B -42.12% 16.37B -17.47% 15.56B +2.77% 13.63B +34.58% 12.27B +77.64% 8.87B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1